Research-use-only (RUO). This page is an educational overview of scientific literature and is not medical advice, not a recommendation, and not a suggestion to use, buy, or administer any compound. Nothing here should be read as telling you what to take.
Search “best peptides for fat loss” and you will find a lot of confident marketing and very little context. A more honest question is: which peptides have actually been studied in the context of fat loss, and what does that research really show? That is what this page covers. It is important to separate three very different things: a compound being most discussed online, a compound being most studied in trials, and a compound being proven to work safely for a given individual. “Most studied” does not mean “best,” and it certainly does not mean “right for you.” Evidence also varies enormously by compound — from large human randomized controlled trials (RCTs) down to animal-only data — so the honest answer is a spectrum, not a winner.
Comparison at a glance
| Peptide | What it’s studied for (re: fat loss) | Evidence tier | Key caveat |
|---|---|---|---|
| Semaglutide (GLP-1 receptor agonist) | Chronic weight management; roughly 10–15% body-weight reduction vs placebo in obesity RCTs | Strong human RCT — approved medicine (marketed as Wegovy) | Prescription drug; GI side effects; weight tends to return after stopping |
| Tirzepatide (GIP/GLP-1 receptor agonist) | Weight reduction; up to ~21% at 72 weeks in an obesity RCT | Strong human RCT — approved medicine (marketed as Zepbound) | Prescription drug; GI side effects; regain after discontinuation |
| Tesamorelin (GHRH analog) | Reducing visceral (deep abdominal) fat in HIV-associated lipodystrophy | Strong human RCT — but narrow population and endpoint | Approved only for HIV lipodystrophy, not general fat loss; visceral fat re-accumulates off-treatment |
| AOD-9604 (human GH fragment) | Lipolysis / fat breakdown | Preclinical (rodent); human obesity trials never led to approval | Not approved for obesity anywhere; prohibited in sport by WADA |
| MOTS-c (mitochondrial-derived peptide) | Glucose/fat metabolism; described as an “exercise mimetic” | Preclinical / mechanistic; no human fat-loss trials | Human data limited to observational exercise studies, not peptide administration |
Compound-by-compound: what the research shows
Semaglutide — strongest human evidence
Semaglutide is a GLP-1 receptor agonist and has the deepest human evidence base of anything on this list. According to PubMed-indexed research, the phase 3 STEP 4 trial reported a mean 10.6% body-weight loss during a 20-week run-in, and participants who continued semaglutide lost a further 7.9% while those switched to placebo regained 6.9% — a 14.8 percentage-point difference (DOI: 10.1001/jama.2021.3224). A meta-analysis of RCTs in people without diabetes found roughly a 10% placebo-subtracted weight reduction. The honest caveat: it is an approved prescription medicine studied under medical supervision, gastrointestinal side effects are common, and weight is regained when treatment stops. For the research-context dosing reference, see the semaglutide dosage calculator.
Tirzepatide — strong human evidence, largest effect sizes
Tirzepatide is a dual GIP/GLP-1 receptor agonist. In the phase 3 SURMOUNT-1 trial, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% across the 5, 10 and 15 mg doses versus −3.1% for placebo, with 91% of the highest-dose group losing at least 5% of body weight (DOI: 10.1056/NEJMoa2206038). A separate phase 3 trial in Chinese adults reproduced double-digit reductions (DOI: 10.1001/jama.2024.9217), and a 2024 network meta-analysis ranked tirzepatide as the most effective anti-obesity pharmacotherapy, ahead of semaglutide. Same caveats apply: prescription medicine, GI effects, and regain after stopping. Research-context dosing details are on the tirzepatide dosage calculator.
Tesamorelin — strong evidence, but for a specific problem
Tesamorelin is a growth-hormone-releasing-hormone analog. It is genuinely backed by human RCTs — but for a narrow purpose. A pooled analysis of two phase 3 trials in people with HIV-associated abdominal fat accumulation showed a ~15.4% reduction in visceral adipose tissue versus placebo, with no clinically significant change in subcutaneous fat and no meaningful overall weight loss (DOI: 10.1210/jc.2010-0490). Its only approved indication is HIV-related lipodystrophy, and visceral fat re-accumulates once treatment ends (DOI: 10.2165/11202240-000000000-00000). It has not been established as a general “fat loss” agent. The dosing reference is the tesamorelin dosage calculator.
AOD-9604 — promising in mice, unproven in humans
AOD-9604 is a fragment of human growth hormone marketed heavily for “fat burning.” The reality is that its fat-loss data are essentially preclinical: in obese mice, chronic dosing reduced body weight and fat and increased lipolytic sensitivity (DOI: 10.1210/endo.142.12.8522). It advanced into human phase 2 obesity trials, but it was never approved as an anti-obesity therapy, and it is now prohibited in sport by the World Anti-Doping Agency (DOI: 10.1002/dta.1715). Rodent fat loss should not be presented as proven human weight loss. See the research reference at the AOD-9604 dosage protocol.
MOTS-c — interesting biology, no human fat-loss trials
MOTS-c is a mitochondrial-derived peptide often called an “exercise mimetic.” In animal and cell studies it enhances glucose handling, activates AMPK, and in mice can increase brown-fat activity and limit fat accumulation (DOI: 10.1016/j.freeradbiomed.2016.05.015; DOI: 10.3389/fendo.2023.1120533). Human evidence is observational only — for example, plasma MOTS-c rises with exercise and has been correlated with fat-mass reduction — not trials of giving MOTS-c to induce fat loss. So for fat loss specifically, MOTS-c is preclinical. The research reference is the MOTS-c dosage protocol.
What the evidence actually supports
Being blunt about the tiers: only semaglutide and tirzepatide have strong, large-scale human RCT evidence for reducing body weight, and both are approved prescription medicines rather than “research peptides” in practice. Tesamorelin has solid human trial data, but only for shrinking visceral fat in a specific clinical population — not for general fat loss, and the effect reverses when stopped. AOD-9604 and MOTS-c are, for fat loss, essentially preclinical: interesting mechanisms in animals with no convincing human weight-loss trials behind them. “Most discussed online” (often AOD-9604 and MOTS-c) is close to the inverse of “best evidenced.” None of this ranks a “best” choice for any individual — it simply maps where the science currently stands.
Important limitations
- Research-use-only. The compounds discussed here are covered as research chemicals. This is educational information, not medical advice and not a protocol to follow.
- Most are not approved for fat loss. Tesamorelin is approved only for HIV lipodystrophy; AOD-9604 and MOTS-c are not approved anti-obesity therapies; semaglutide and tirzepatide are prescription-only medicines used under clinical supervision.
- Individual results and safety are unknown. Efficacy figures come from controlled trials in defined populations and do not predict outcomes, side effects, or interactions for any specific person. Product purity and identity outside regulated supply chains are not guaranteed.
- Talk to a qualified healthcare professional before making any decision about weight, metabolic health, or any substance. For unit-conversion and reconstitution math in a research context only, see the peptide dosage calculator.
FAQ
Which peptide has the strongest evidence for fat loss?
By trial quality and size, tirzepatide and semaglutide have by far the strongest human RCT evidence, and a 2024 meta-analysis ranked tirzepatide highest for weight reduction. Both are approved prescription medicines, not over-the-counter research peptides, and this is not a recommendation to use either.
Are AOD-9604 and MOTS-c “proven” for fat loss?
No. Their fat-loss data are largely from rodents and cell studies. AOD-9604 was never approved for obesity and is banned in sport; MOTS-c has no human trials testing it as a fat-loss treatment. Presenting them as proven human fat-loss agents would be inaccurate.
Why is tesamorelin listed if it’s not a general weight-loss drug?
Because it is frequently searched alongside “fat loss” and does have strong human data — but specifically for reducing visceral abdominal fat in HIV-associated lipodystrophy, with fat re-accumulating after treatment stops. It is a good example of why the endpoint and population behind a study matter as much as the headline.
Sources are peer-reviewed literature indexed in PubMed and ClinicalTrials.gov (see citations). This overview is educational, research-use-only, and not a substitute for professional medical guidance.
